What is vaginal cytology?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Vaginal Cytology?

Vaginal cytology is a microscopic examination of cells collected from the vaginal cuff (the top of the vagina after hysterectomy) or vaginal walls, used primarily for surveillance in specific high-risk populations rather than routine screening. 1

Definition and Purpose

Vaginal cytology involves collecting cells from the vaginal surface using sampling instruments similar to those used for cervical cancer screening. 1 The test examines these cells microscopically to detect:

  • Vaginal intraepithelial neoplasia (VAIN) - precancerous changes in vaginal tissue 2
  • Vaginal cancer - though this is extremely rare (1-2 cases per 100,000 women per year) 1
  • Recurrent disease in women with prior cervical or endometrial cancer 3, 4

When Vaginal Cytology is Indicated

Vaginal cytology should NOT be performed routinely in most women after hysterectomy. 1 The test is only appropriate in specific high-risk situations:

Women Who Should Receive Vaginal Cytology:

  • History of cervical cancer - continue screening indefinitely while in reasonable health 1, 3
  • History of CIN2/3 (high-grade cervical precancer) - continue for 20-25 years after treatment, even beyond age 65 3
  • In utero DES (diethylstilbestrol) exposure - lifelong increased risk of vaginal cancer 1, 3
  • Immunocompromised patients (HIV+, transplant recipients, chronic immunosuppression) 3
  • Recent hysterectomy for CIN2/3 - every 4-6 months until three consecutive negative tests over 18-24 months 1

Women Who Should NOT Receive Vaginal Cytology:

Women who had hysterectomy for benign conditions (fibroids, bleeding, prolapse) should not undergo vaginal cytology screening. 1, 5 The evidence is clear:

  • In 5,862 women screened after benign hysterectomy, the positive predictive value for vaginal cancer was 0% 1
  • 663 vaginal cytology tests were needed to detect one case of dysplasia, with no cancers found 1
  • No benefit in patient outcomes was demonstrated 1

Collection Technique

Vaginal cytology samples are obtained from the vaginal cuff (the closed top of the vagina after cervix removal), not from the vaginal walls or pool. 1 The sampling uses:

  • Extended tip spatula or cervical broom to sample the vaginal cuff circumferentially 1
  • Either conventional smear (cells placed on slide) or liquid-based cytology 1
  • Timing is flexible with liquid-based cytology; conventional smears ideally collected 10-20 days after menses starts 1

Important Clinical Distinctions

Vaginal cytology is fundamentally different from cervical cytology (Pap test). 1 Key differences:

  • Cervical cytology screens for cervical cancer in women with an intact cervix 1
  • Vaginal cytology only evaluates the vaginal cuff after the cervix has been removed 1
  • Vaginal cytology has much lower sensitivity and clinical utility than cervical cytology 5, 4

Test Performance Characteristics

The accuracy of vaginal cytology is limited:

  • Sensitivity for detecting vaginal recurrence after endometrial cancer: 40% 4
  • Specificity: 87.9% 4
  • Positive predictive value: 7.3% (most abnormal results are false positives) 4
  • Negative predictive value: 98.4% 4

Common Clinical Pitfalls

Never perform vaginal cytology without first confirming the indication through medical record review. 1, 3 Specific errors to avoid:

  • Screening women after benign hysterectomy - this provides no benefit and leads to unnecessary interventions 1, 5
  • Stopping surveillance too early in women with prior CIN2/3 - must continue for 20-25 years regardless of age 3
  • Relying on patient verbal history alone - always verify hysterectomy indication through pathology reports 1, 3
  • Performing colposcopy for atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL) results - these do not require colposcopy 4

Management of Abnormal Results

When abnormal vaginal cytology is detected in appropriate surveillance populations, immediate colposcopy with directed biopsy is recommended. 2 The algorithm depends on findings:

  • Negative biopsy: Repeat HPV and cytology in 6-12 months 2
  • VAIN 1 (low-grade): Observation with repeat colposcopy and HPV testing in 6 months 2
  • VAIN 2/3 or cancer: Treatment per oncology guidelines 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of HPV E6/7 on Vaginal Cuff in Post-Hysterectomy Patient

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cervical Cancer Screening Beyond Age 65

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.